The use of psilocybin and MDMA by psychiatrists has been approved by the drug regulator.
These substances can be used to treat patients suffering from severe mental health disorders.
The Therapeutic Goods Administration (TGA) said that the approval of the drugs for the treatment of mental health disorders was prompted by the lack of effective options for those suffering from treatment-resistant conditions.
Starting July 1, the agency will restrict the prescribing of these substances to only authorized psychiatrists.
It also noted that the drugs cannot be used outside of PTSD or other treatment-resistant conditions.
Currently, there are no products that contain either MDMA or psilocybin that have been approved by the agency to treat mental health disorders.
However, through an amendment, psychiatrists can now legally supply these substances to patients.
The ruling by the agency was welcomed by a mental health organization in Australia.
Peter Hunt, the chairman of the organization, said the approval of the drugs was a victory for those who suffer from mental health disorders.
It shows that the agency recognizes the need for effective treatment options for those with treatment-resistant conditions.
Although these drugs are not yet registered on the official list of medicines for treating mental health disorders, the approval by the agency will allow patients with these conditions to access them through authorized psychiatrists.